Form 4: Charles River Laboratories Executive Joseph LaPlume Reports RSU Grant and Tax Withholding

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported the acquisition of restricted stock units and a subsequent disposition for tax purposes.

Summary

• Joseph W. LaPlume, Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International, Inc. (CRL), reported changes in his beneficial ownership of company common stock.
• On May 30, 2025, Mr. LaPlume acquired 6,709 shares of common stock at a price of $135.63 per share, identified as an acquisition of unvested restricted stock units (RSUs).
• These RSUs are scheduled to vest annually on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.
• Following this acquisition, Mr. LaPlume's beneficial ownership increased to 25,856 shares.
• On May 31, 2025, Mr. LaPlume disposed of 155 shares of common stock at the same price of $135.63 per share, which is typically a transaction for the payment of tax liabilities related to the vesting of equity awards.
• After the disposition, Mr. LaPlume's beneficial ownership stands at 25,701 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates ongoing executive incentive alignment and retention through standard equity compensation, which is generally viewed favorably by investors as it ties management's interests to long-term company performance. There are no negative surprises or adverse events reported.

Positives

• The grant of 6,709 restricted stock units to a key executive like Joseph W. LaPlume aligns management's interests with long-term shareholder value, as the value of these units is tied to the company's stock performance.
• The multi-year vesting schedule (through May 2029) encourages executive retention and sustained focus on the company's strategic objectives.

Negatives

• No specific negative implications are evident from this routine insider transaction report.

Future Outlook

The document indicates a future outlook for executive compensation, with the granted restricted stock units vesting annually on May 30th from 2026 through 2029, providing a long-term incentive for the executive.

Industry Context

This Form 4 filing reflects a standard practice of executive compensation within the life sciences and contract research organization (CRO) industry, where equity grants like restricted stock units are commonly used to attract, retain, and incentivize key management personnel. Such grants align executive performance with shareholder returns over the long term.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a key executive aligns management's long-term interests with those of shareholders, potentially leading to improved company performance and shareholder value.
• Employees (Executive): Joseph W. LaPlume receives a significant equity grant, enhancing his compensation and providing a strong incentive for continued dedication to the company's strategic growth.

Next Steps

• Annual vesting of the restricted stock units on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.

Key Dates

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Stock Ownership, Corporate Strategy, Biotechnology Services